Gilead Sciences (NASDAQ:GILD) is predicted to report a better This fall revenue on decrease income Tuesday night, with traders watching to see how the corporate’s Hepatitis C and HIV franchises are faring.
Analysts, on common, estimate Gilead will put up an adjusted revenue of $1.76 per share, in contrast with $1.67 for a similar quarter in 2022. Revenue is anticipated at $7.10B, down from $7.39B the prior yr.
For Q3 2023, Gilead reported comparatively flat year-over-year income due partly to decrease gross sales of its HCV merchandise and COVID-19 therapy Veklury, also called remdesivir. Certain HIV medicine additionally underperformed. Despite slowed gross sales, the corporate nonetheless managed to beat the Street on the highest and backside strains.
Gilead has exceeded Street income estimates for the previous 8 quarters. It’s managed to prime EPS estimates 5 occasions, however has missed 3 occasions. Over the previous 90 days, 22 analysts have raised their This fall estimates for the corporate, whereas 2 have lowered them.
Gilead watchers may even be seeking to see if the corporate achieves the 2023 forecast it issued in Q3. The firm raised its full-year gross sales outlook to the vary of $26.7B to $26.9B, up from its prior view of $26.3B to $26.7B. The gross sales estimate for Veklury was raised to $1.9B from $1.7B.
Analysts, on common, anticipate Gilead to report 2023 income of $27.08B.